What is the recommended dosing regimen for deoxycholic acid (Kybella) for a patient with fat under the chin (submentum area)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Deoxycholic Acid Dosing for Submental Fat Reduction

The FDA-approved dosing regimen for deoxycholic acid (Kybella) is 2 mg/cm² injected into the submental fat, with each treatment session consisting of up to 50 injections of 0.2 mL each (maximum 10 mL total per session), spaced 1 cm apart, with up to 6 treatment sessions administered at intervals of no less than 1 month apart. 1

Specific Dosing Parameters

Single Treatment Session:

  • Dose concentration: 2 mg/cm² of treatment area 1
  • Maximum injections per session: 50 injections 1
  • Volume per injection: 0.2 mL 1
  • Maximum total volume per session: 10 mL 1
  • Injection spacing: 1 cm apart 1

Treatment Course:

  • Maximum number of sessions: Up to 6 treatments 1
  • Minimum interval between sessions: 1 month (approximately 28 days) 1, 2
  • Average sessions required: Most patients need 3-4 sessions, with clinical trials showing 3.4 sessions on average 3

Critical Anatomical Considerations to Avoid Complications

Marginal Mandibular Nerve Protection:

  • Do NOT inject above the inferior border of the mandible 1
  • Do NOT inject within 1-1.5 cm below the inferior border of the mandible (from angle to mentum) to avoid nerve injury causing asymmetric smile 1
  • Only inject within the designated target submental fat treatment area 1

Platysma Muscle Avoidance:

  • Palpate the submental area before each treatment to identify pre-platysmal fat (subcutaneous fat between dermis and platysma) 1
  • Avoid injecting into the platysma muscle itself 1

Patient Selection Criteria

Screen for contraindications:

  • Rule out thyromegaly and cervical lymphadenopathy as alternative causes of submental fullness 1
  • Exercise caution in patients with excessive skin laxity or prominent platysmal bands, as fat reduction may produce aesthetically undesirable outcomes 1
  • Use caution in patients with prior surgical or aesthetic submental procedures due to altered anatomy and scar tissue 1

Expected Efficacy and Timeline

Treatment Response:

  • 59-65% of patients achieve ≥1-point improvement on the Clinician-Reported Submental Fat Rating Scale 2
  • 53-66% of patients report satisfaction with face/chin appearance 2
  • Significant objective volume reduction confirmed by caliper measurements 4, 3
  • Results assessed 12 weeks after the final treatment session 5, 2

Immediate Post-Treatment Changes:

  • Expect an average 8.68% increase in submental volume during the immediate recovery period due to edema 3
  • This swelling is self-resolving 3

Common Adverse Effects and Management

Expected Treatment-Area Reactions (typically mild-to-moderate and self-resolving):

  • Edema (most common) 5, 6
  • Local pain 6
  • Bruising 6
  • Numbness/paresthesia (occurs in all patients but self-resolves) 3
  • These typically resolve within approximately one treatment interval (1 month) 5

Serious Complications to Monitor:

  • Marginal mandibular nerve injury (presents as asymmetric smile from lip depressor paresis) 1
  • Skin necrosis 6
  • Alopecia 6
  • Vascular events 6

Administration Requirements

Provider qualifications:

  • Must be administered by a healthcare professional 1
  • Provider must understand submental anatomy and neuromuscular structures 1
  • Consider use of ice/cold packs, topical or injectable local anesthesia 1

Product inspection:

  • Solution should be clear, colorless, and free of particulate matter 1
  • Discard vial if discolored or contains particulates 1
  • Discard any remaining solution after use 1

Key Clinical Pitfalls

  • Never exceed 50 injections or 10 mL per treatment session to avoid excessive tissue damage 1
  • Never inject closer than 1-1.5 cm below the mandibular border to prevent nerve injury 1
  • Do not use in areas outside the submental region, as safety and efficacy have not been established 1
  • Patient recovery scores improve with subsequent treatments, so counsel patients that early sessions may have more pronounced side effects 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.